Di
Dicerna (Novo)
Lexington MAFounded 2006200 employees
Private CapbiotechAcquiredHepatologyCardiology
Platform: GalXC RNAi
Market Cap
N/A
All Drugs
2
Clinical Trials
6
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Bemasotorasib | DIC-2649 | Phase 1/2 | 2 | GIP-R | PAH | ||
| DIC-4437 | DIC-4437 | Approved | 4 | PD-L1 | RA |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (6)